Back to All Resources

Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

June 1, 2022

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

IRAKIMiD_ASCO_ThumbNail
View Poster
Area of Focus
Oncology
Programs
IRAKIMiD (KT-413)
Indications
MYD88 Tumors
Development Stage
Clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

August 24, 2022
Discovery and characterization of potent degraders of IRAK4 and IMiD substrates for oncology indications
ACS Fall 2022
MYD88 Tumors
View Resource
June 26, 2022
Discovery of IRAKIMiDs: Dual-Mechanism Degraders Targeting IRAK4 and IMiDSubstrates for Oncology
37th ACS National Medicinal Chemistry Symposium
MYD88 Tumors
View Resource